Press Release **For immediate distribution**

Ichnos Glenmark Innovation reports the publication in Nature Communications of the preclinical development of ISB 1442 bispecific antibody for Treatment of Relapsed/Refractory Multiple Myeloma

- *ISB 1442 is a first in class biparatopic CD38 x CD47 bispecific antibody based on the BEAT® antibody technology with the ability to induce synthetic immunity via multiple effector mechanisms.*
- *ISB 1442 exhibited superiority against daratumumab in cell lines in vitro, as well as in primary multiple myeloma patient's samples ex vivo, and it also induced complete eradication of tumors in preclinical mouse models in vivo.*

New York, USA, March 08, 2024: Ichnos Glenmark Innovation (IGI), an alliance between Ichnos Sciences Inc., a global fully-integrated clinical-stage biotech company, announced that Nature Communications - peer-reviewed, open access, scientific journal - published a manuscript describing the pre-clinical development of ISB 1442, a CD38 and CD47 Bispecific Biparatopic Antibody Innate Cell Modulator (online manuscript available here). ISB 1442 is currently being tested in a Phase I clinical trial in relapsed refractory multiple myeloma.

"The acceptance of our manuscript by Nature Communications signifies the high quality of research conducted at Ichnos Glenmark Innovation, particularly in the challenging field of multiple myeloma. Our ongoing Phase I trial is a testament to our commitment to advancing care for patients battling this complex disease. We are eager to present further data to the medical community before the end of this year, highlighting our continuous efforts to innovate and improve patient outcomes," said Cyril Konto, President, CEO and Board Member of Ichnos Glenmark Innovation.

Collaboration propels innovation

ISB 1442 is a multispecific antibody, rationally designed to harness innate immunity to treat CD38+ hematologic malignancies. ISB 1442 antibody is unique due to three features: (i) it uses two distinct Fab arms to target the CD38 tumor associated antigen (biparatopic approach), allowing for improved Complement Dependent Cytotoxicity (CDC) and improved binding to tumor cells when an antigen is downregulated; (ii) it blocks the CD47 'don't eat me' signal to counteract tumor escape from phagocytosis, leveraging selective avidity-induced binding to CD38+ tumor cells, thereby avoiding off-tumor targeting; and (iii) it is equipped with the Fc mutations enhancing effector mechanisms (CDC, Antibody Dependent Cell Cytotoxicity and Antibody Dependent Cell Phagocytosis).

FIRST-IN-CLASS ISB 1442 KEY ATTRIBUTES



MODES OF ACTION



CDC: Complement Dependent Cytotoxicity
ADCC: Antibody Dependent Cell Cytotoxicity
ADCP: Antibody Dependent Cell Phagocytosis

The flexibility of the BEAT® (**B**ispecific **E**ngagement by **A**ntibodies based on the **T**CR) platform enabled straightforward integration of all these features into a single antibody molecule.

Impactful pre - clinical study outcome

On cell lines, ISB 1442 showed superior tumor cell killing against daratumumab or to the combination of daratumumab with an anti-CD47 mAb (hu5F9). This implies that the engineering and architecture of ISB 1442 possesses improved effector functions compared to standard anti-CD38 monoclonal antibodies as well as their combination with CD47 blocking agents.

ISB 1442 consistently demonstrated superior tumor growth inhibition compared to daratumumab in preclinical mouse models *in vivo* and higher killing of tumor cells in primary multiple myeloma patient's samples *ex vivo*, including in patients that relapsed from anti-CD38 therapies. This suggests that ISB 1442 could be effective as monotherapy as well as salvage therapy. Altogether, ISB 1442 may represent an improved therapeutic option available for the treatment of multiple myeloma patients relative to other monospecific anti-CD38 antibodies.

--End--

About Ichnos Glenmark Innovation

Ichnos Glenmark Innovation (IGI) is an alliance between Ichnos Sciences Inc., a global fully-integrated clinical-stage biotech company developing multispecifics™ and small molecules in oncology, with the aim to accelerate new drug discovery in cancer treatment. IGI combines Ichnos' research and development proficiencies in novel biologics with those of Glenmark's in new small molecules to continue developing cutting-edge therapy solutions that treat hematological malignancies and solid tumors. Harnessing the combined proficiency of over 150 scientists and a robust pipeline of novel molecules, this collaboration will leverage the capabilities of its three global centers of innovation spread across the USA, Switzerland and India to propel Innovation.

For more information, visit www.iginnovate.com.

For more information, please contact:

IGI Corporate Communications Team
Corporate.communications@iginnovate.com